Dr. Brad Eilerman

<i>Bradley Eilerman, MD</i> graduated cum laude from Centre College with a B.S. in Molecular Biology and Biochemistry. He obtained his M.D. with high distinction from the University of Kentucky where he was inducted in the Alpha Omega Alpha honor society and was awarded the Endocrine Society Achievement Award. He is currently a candidate for a Masters in Health Informatics at Northern Kentucky University. Brad completed his internship in Internal Medicine and Pediatrics at Vanderbilt Medical Center and finished his residency at The University Hospital of Cincinnati and Children’s Hospital Medical Center. He went on to fellowship training in Adult Neurodevelopmental Disabilities at Cincinnati Children’s Hospital and Diabetes, Endocrinology and Metabolism at the University of Cincinnati. He holds board certifications in Internal Medicine, Pediatrics, Endocrinology, Diabetes and Metabolism and Obesity Medicine. Brad currently works as a clinical endocrinologist at the St. Elizabeth Regional Diabetes Center in the Greater Cincinnati area. Brad is currently on the speaker’s board of Sanofi, Novo Nordisk, Glaxo Smith Klein, BMS, Amylin, Merck, BI, Vivus, Amarin and Abbott Pharmaceuticals. He is sub-Investigator in clinical trials for Sanofi, Amylin, and Orexigen. He developed insulin dosing software as co-founder of Endometrix LLC and is currently in the process of launching a product with a major pharmaceutical company.